Baxter throws $500m behind CMS push for dialysis innovation

Baxter (NYSE:BAX) officials apparently think their company can benefit from a Trump administration and CMS proposal to provide extra reimbursement for new and innovative dialysis equipment and supplies.

Just days ago, CEO Joe Almeida told analysts in an earnings call that the company planned to invest $500 million to significantly increase production capacity and meet new patients’ needs amid the push to adopt home dialysis across the United States.

The proposed CMS rule and the Advancing American Kidney Health Initiative are “putting once-in-a-generation policies in place to improve the lives of those with kidney disease,” Laura Angelini, general manager of Baxter’s Renal Care business, said today in a news release.

Get the full story on our sister site MassDevice. 

Engineering Better Devices at DeviceTalks Minnesota DeviceTalks Minnesota's engineering track is designed to provide attendees with with actionable lessons in a peer-to-peer format on topics such as: Human factors engineering Patient-centric device development R&D trends Manufacturing and scalability Navigating the product development process from start to finish "How We Built This" panels with top medical device groups Join industry leaders and medical device professionals at the most awaited medtech conference of the year, DeviceTalks Minnesota. Use code DT15 to save 15%! REGISTER NOW